Full Text
The Full Text of this article is available as a PDF (32.9 KB).
editorial . 2000 Jun 2;83(1):6–7. doi: 10.1054/bjoc.2000.1277
What can we learn from phase II adjuvant trials in melanoma?
U Keilholz
1, S Suciu
2, A M M Eggermont
3
U Keilholz
1Immunotherapy/Chemotherapy Subgroup, EORTC Melanoma Cooperative Group, Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, Berlin, 12200, Germany
Find articles by U Keilholz
S Suciu
2EORTC Data Centre, av E. Mounier 83 bte 11, Brussels, 1200, Belgium
Find articles by S Suciu
A M M Eggermont
3EORTC Melanoma Cooperative Group, Department of Surgical Oncology, University Hospital Rotterdam – Daniel den Hoed Cancer Center, Groene Hilledijk 301, Rotterdam, EA, 3075, The Netherlands
Find articles by A M M Eggermont
1Immunotherapy/Chemotherapy Subgroup, EORTC Melanoma Cooperative Group, Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, Berlin, 12200, Germany
2EORTC Data Centre, av E. Mounier 83 bte 11, Brussels, 1200, Belgium
3EORTC Melanoma Cooperative Group, Department of Surgical Oncology, University Hospital Rotterdam – Daniel den Hoed Cancer Center, Groene Hilledijk 301, Rotterdam, EA, 3075, The Netherlands
Issue date 2000 Jul.
Copyright © 2000 Cancer Research Campaign
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
PMCID: PMC2374544 PMID: 10883660